Literature DB >> 20463470

Recent insights into factors affecting remnant lipoprotein uptake.

Kevin Jon Williams1, Keyang Chen.   

Abstract

PURPOSE OF REVIEW: Remnant lipoproteins that persist in the bloodstream after each meal have become increasingly important contributors to atherosclerotic vascular disease, owing to the spread of overnutrition, underexertion, obesity, insulin resistance, and type 2 diabetes. Here, we review recent work that clarified long-standing controversies over the molecular mediators of remnant clearance by the liver, as well as their dysregulation - but possible correction - during alterations in caloric balance. RECENT
FINDINGS: Two endocytic receptors, the syndecan-1 heparan sulfate proteoglycan (HSPG) and the LDL receptor, plus one docking receptor, SR-BI, significantly contribute to normal hepatic remnant catabolism. Compelling evidence exists for dysfunction of the syndecan-1 HSPG in diabetic states. The major molecular defect identified so far in poorly controlled type 1 diabetes is impaired hepatic HSPG assembly. In contrast, the primary defect in hepatic HSPGs in type 2 diabetes appears to arise from accelerated de-sulfation, owing to the induction of a sulfatase. Moreover, short-term caloric restriction restores hepatic expression of this sulfatase towards normal.
SUMMARY: Correct identification of hepatic remnant receptors has finally allowed investigations of their molecular dysregulation in diabetes and related conditions. New work points to novel therapeutic targets to correct postprandial dyslipoproteinemia and its consequent arterial damage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20463470     DOI: 10.1097/MOL.0b013e328338cabc

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  31 in total

1.  Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia.

Authors:  H Carlijne Hassing; Hans Mooij; Shuling Guo; Brett P Monia; Keyang Chen; Wim Kulik; Geesje M Dallinga-Thie; Max Nieuwdorp; Erik S G Stroes; Kevin Jon Williams
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

2.  Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins.

Authors:  Keyang Chen; Ming-Lin Liu; Lana Schaffer; Mingzhen Li; Guenther Boden; Xiangdong Wu; Kevin Jon Williams
Journal:  Hepatology       Date:  2010-11-03       Impact factor: 17.425

3.  Globular warming: how fat gets to the furnace.

Authors:  Kevin Jon Williams; Edward A Fisher
Journal:  Nat Med       Date:  2011-02       Impact factor: 53.440

Review 4.  Lipid Nanoparticle Systems for Enabling Gene Therapies.

Authors:  Pieter R Cullis; Michael J Hope
Journal:  Mol Ther       Date:  2017-04-13       Impact factor: 11.454

5.  Molecular mediators for raft-dependent endocytosis of syndecan-1, a highly conserved, multifunctional receptor.

Authors:  Keyang Chen; Kevin Jon Williams
Journal:  J Biol Chem       Date:  2013-03-22       Impact factor: 5.157

6.  Dietary unsaturated fat increases HDL metabolic pathways involving apoE favorable to reverse cholesterol transport.

Authors:  Allyson M Morton; Jeremy D Furtado; Carlos O Mendivil; Frank M Sacks
Journal:  JCI Insight       Date:  2019-04-04

7.  SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus.

Authors:  H Carlijne Hassing; R Preethi Surendran; Bruno Derudas; An Verrijken; Sven M Francque; Hans L Mooij; Sophie J Bernelot Moens; Leen M 't Hart; Giel Nijpels; Jacqueline M Dekker; Kevin Jon Williams; Erik S G Stroes; Luc F Van Gaal; Bart Staels; Max Nieuwdorp; Geesje M Dallinga-Thie
Journal:  Obesity (Silver Spring)       Date:  2014-01-09       Impact factor: 5.002

8.  Suppression of Hepatic FLOT1 (Flotillin-1) by Type 2 Diabetes Mellitus Impairs the Disposal of Remnant Lipoproteins via Syndecan-1.

Authors:  Keyang Chen; Qingsi Wu; Kongwang Hu; Chengwei Yang; Xiangdong Wu; Peter Cheung; Kevin Jon Williams
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-21       Impact factor: 8.311

9.  Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk.

Authors:  Allyson M Morton; Manja Koch; Carlos O Mendivil; Jeremy D Furtado; Anne Tjønneland; Kim Overvad; Liyun Wang; Majken K Jensen; Frank M Sacks
Journal:  JCI Insight       Date:  2018-02-22

10.  Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.

Authors:  Jon C Gonzales; Philip L S M Gordts; Erin M Foley; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2013-05-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.